Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
59.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ultragenyx Pharmaceutical Inc
Wall Street
Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
RARE
is 94.28 USD
with a low forecast of 48.48 USD and a high forecast of 147 USD.
RARE Last Price Targets
Ultragenyx Pharmaceutical Inc
The latest public price target was made on Nov 6, 2024 by
Ed Arce
from
H.C. Wainwright
,
who expects
RARE
stock to
rise by 115%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Ed Arce
H.C. Wainwright
|
95
USD
Upside 115% |
1 month ago
Nov 6, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright
StreetInsider
|
|
Joseph Schwartz
Leerink Partners
|
85
USD
Upside 92% |
1 month ago
Nov 6, 2024
|
Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Salveen Richter
Goldman Sachs
|
67
USD
Upside 52% |
6 months ago
Jun 6, 2024
|
Goldman Sachs Upgrades Ultragenyx Pharma (RARE) to Buy
StreetInsider
|
Dae Gon Ha
Stifel Nicolaus
|
127
USD
Upside 187% |
6 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $127 at Stifel
StreetInsider
|
Christopher Raymond
Raymond James
|
135
USD
Upside 205% |
6 months ago
May 31, 2024
|
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Joel Beatty
Robert W. Baird
|
72
USD
Upside 63% |
6 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $72 at Baird
StreetInsider
|
Whitney Ijem
Canaccord Genuity
|
111
USD
Upside 151% |
6 months ago
May 31, 2024
|
Ultragenyx Pharma (RARE) PT Raised to $111 at Canaccord Genuity
StreetInsider
|
|
Dae Gon Ha
Stifel Nicolaus
|
124
USD
Upside 180% |
8 months ago
Apr 15, 2024
|
Stifel Reiterates Buy Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
|
Christopher Raymond
Raymond James
|
130
USD
Upside 194% |
8 months ago
Apr 15, 2024
|
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
StreetInsider
|
Unknown Analyst
Morgan Stanley
|
95
USD
Upside 115% |
1 year ago
Feb 3, 2023
|
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RARE's stock price target?
Price Target
94.28
USD
According to Wall Street analysts, the average 1-year price target for
RARE
is 94.28 USD
with a low forecast of 48.48 USD and a high forecast of 147 USD.
What is Ultragenyx Pharmaceutical Inc's Revenue forecast?
Projected CAGR
34%
The
compound annual growth rate
of Ultragenyx Pharmaceutical Inc's revenue for the next 4 years is
34%.
You don't have any saved screeners yet
